Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Year in Review
  • Published:

Neuro-oncology in 2013

Improving outcome in newly diagnosed malignant glioma

Subjects

In 2013, two discoveries—that alkylating agent chemotherapy prolongs survival when added to radiotherapy for patients with anaplastic oligodendroglial tumours with 1p19q codeletion, and that bevacizumab prolongs progression-free survival in patients with newly diagnosed glioblastoma—have dominated debate in neuro-oncology. These findings could help to define new standards of care in malignant glioma.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1: An IDH-driven approach to diffuse and malignant gliomas.

References

  1. Weller, M. et al. Molecular neuro-oncology in clinical practice: a new horizon. Lancet Oncol. 14, e370–e379 (2013).

    Article  CAS  Google Scholar 

  2. Sturm, D. et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 22, 425–437 (2012).

    Article  CAS  Google Scholar 

  3. Brennan, C. W. et al. The somatic genomic landscape of glioblastoma. Cell 155, 462–467 (2013).

    Article  CAS  Google Scholar 

  4. Van den Bent, M. et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC Brain Tumor Group Study 26951. J. Clin. Oncol. 31, 344–350 (2013).

    Article  CAS  Google Scholar 

  5. Cairncross, G. et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J. Clin. Oncol. 31, 337–343 (2013).

    Article  CAS  Google Scholar 

  6. Wick, W. et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J. Clin. Oncol. 27, 5874–5880 (2009).

    Article  CAS  Google Scholar 

  7. Wick, W. et al. Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation. Neurology 81, 1515–1522 (2013).

    Article  CAS  Google Scholar 

  8. Chinot, O. et al. Bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastoma. N. Engl. J. Med. (in press).

  9. Gilbert, M. R. et al. Phase III double-blind placebo-controlled trial evaluating bevacizumab (Bev) in patients (Pts) with newly diagnosed glioblastoma (GBM). N. Engl. J. Med. (in press).

  10. Wefel, J. S. et al. Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol. 13, 660–668 (2011).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Michael Weller.

Ethics declarations

Competing interests

M. Weller has received research grants from Isarna Therapeutics, Bayer, Merck Serono, MSD and Roche, and honoraria for lectures or advisory boards from Isarna Therapeutics, MagForce, Merck Serono, MSD and Roche. He was the principal investigator of phase II or phase III trials investigating temozolomide (MSD) in newly diagnosed anaplastic glioma and glioblastoma, as well as recurrent glioblastoma and bevacizumab in glioblastoma. W. Wick has received consulting and lecture fees from MSD, Roche and MagForce, and has received research support from Apogenix, Boehringer Ingelheim, Eli Lilly, MSD and Roche. He serves on the Steering Committee of the AVAglio trial involving bevacizumab in glioblastoma and has been lead investigator in glioma trials involving temozolomide, bevacizumab, enzastaurin and APG101.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Cite this article

Weller, M., Wick, W. Improving outcome in newly diagnosed malignant glioma. Nat Rev Neurol 10, 68–70 (2014). https://doi.org/10.1038/nrneurol.2013.268

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneurol.2013.268

This article is cited by

Search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer